ETFs positioned on Ipsen

Name YTD change Weight AuM
+12.29%-.--% 27,154 M€
+7.89%-.--% 92 M€
+10.53%-.--% 13 M€
+7.65%-.--% 49 M€
+0.81%-.--% 51 M€
+10.13%-.--% 66 M€
+9.38%-.--% 24,432 M€
+8.05%-.--% 75 M€
+11.24%-.--% 67 M€
+7.44%-.--% 6 M€
+5.06%-.--% 1,193 M€
+7.25%-.--% 6,576 M€
+9.20%-.--% 3,469 M€
+9.41%-.--% 5,871 M€
0.00%4.67% 8 M€
+61.02%3.96% 215 M€
+10.57%3.25% 23 M€
+12.43%1.94% 31 M€
+8.58%1.94% 31 M€
+2.08%1.75% 574 M€
+9.06%1.54% 18 M€
+8.51%1.52% 17 M€
+10.20%1.48% 160 M€
0.00%1.05% 208 M€
0.00%1.05% 26 M€
+8.02%0.98% 125 M€
+7.46%0.87% 730 M€
+6.51%0.83% 55 M€
+6.27%0.83% 20 M€
+20.69%0.79% 1,260 M€
+10.63%0.78% 103 M€
+9.70%0.59% 140 M€
+1.41%0.58% 38 M€
+6.53%0.54% 51 M€
+7.20%0.53% 40 M€
+5.46%0.5% 23 M€
+8.97%0.47% 937 M€
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535